CD34+ selected cells in clinical transplantation

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

The CD34 antigen is expressed by early hematopoietic stem cells and progenitors and is detected on the surface of approximately 1% of bone marrow mononuclear cells [1-3]. Several monoclonal antibody-based methods have been developed to isolate these cells from clinical samples of bone marrow or peripheral blood based on their expression of this antigen, utilizing either biotin-avidin affinity, panning or immunomagnetic beads. Roughly 50% of CD34+ cells, with 20-90% purity, are recovered from clinical samples using these methods. Several clinical trials have demonstrated hematopoietic recovery using CD34+ selected cells to support high dose therapy. CD34+ cells may be useful in several areas of clinical stem cell transplantation, including purging of tumor cells, T cell depletion, stem cell expansion and gene therapy. This paper reviews the current methods for purification of CD34+ cells from clinical samples and discusses potential uses of these cells in transplantation.

Original languageEnglish (US)
Pages (from-to)577-585
Number of pages9
JournalStem Cells
Volume12
Issue number6
StatePublished - 1994

Fingerprint

Transplantation
CD34 Antigens
Avidin
Cell Transplantation
Stem Cell Transplantation
Biotin
Cell- and Tissue-Based Therapy
Hematopoietic Stem Cells
Bone Marrow Cells
Genetic Therapy
Stem Cells
Bone Marrow
Monoclonal Antibodies
Clinical Trials
T-Lymphocytes
Antigens
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Cell Biology

Cite this

CD34+ selected cells in clinical transplantation. / Collins, R. H.

In: Stem Cells, Vol. 12, No. 6, 1994, p. 577-585.

Research output: Contribution to journalArticle

@article{8ac47977aa594944a1791d81bc4bdd40,
title = "CD34+ selected cells in clinical transplantation",
abstract = "The CD34 antigen is expressed by early hematopoietic stem cells and progenitors and is detected on the surface of approximately 1{\%} of bone marrow mononuclear cells [1-3]. Several monoclonal antibody-based methods have been developed to isolate these cells from clinical samples of bone marrow or peripheral blood based on their expression of this antigen, utilizing either biotin-avidin affinity, panning or immunomagnetic beads. Roughly 50{\%} of CD34+ cells, with 20-90{\%} purity, are recovered from clinical samples using these methods. Several clinical trials have demonstrated hematopoietic recovery using CD34+ selected cells to support high dose therapy. CD34+ cells may be useful in several areas of clinical stem cell transplantation, including purging of tumor cells, T cell depletion, stem cell expansion and gene therapy. This paper reviews the current methods for purification of CD34+ cells from clinical samples and discusses potential uses of these cells in transplantation.",
author = "Collins, {R. H.}",
year = "1994",
language = "English (US)",
volume = "12",
pages = "577--585",
journal = "Stem Cells",
issn = "1066-5099",
publisher = "AlphaMed Press",
number = "6",

}

TY - JOUR

T1 - CD34+ selected cells in clinical transplantation

AU - Collins, R. H.

PY - 1994

Y1 - 1994

N2 - The CD34 antigen is expressed by early hematopoietic stem cells and progenitors and is detected on the surface of approximately 1% of bone marrow mononuclear cells [1-3]. Several monoclonal antibody-based methods have been developed to isolate these cells from clinical samples of bone marrow or peripheral blood based on their expression of this antigen, utilizing either biotin-avidin affinity, panning or immunomagnetic beads. Roughly 50% of CD34+ cells, with 20-90% purity, are recovered from clinical samples using these methods. Several clinical trials have demonstrated hematopoietic recovery using CD34+ selected cells to support high dose therapy. CD34+ cells may be useful in several areas of clinical stem cell transplantation, including purging of tumor cells, T cell depletion, stem cell expansion and gene therapy. This paper reviews the current methods for purification of CD34+ cells from clinical samples and discusses potential uses of these cells in transplantation.

AB - The CD34 antigen is expressed by early hematopoietic stem cells and progenitors and is detected on the surface of approximately 1% of bone marrow mononuclear cells [1-3]. Several monoclonal antibody-based methods have been developed to isolate these cells from clinical samples of bone marrow or peripheral blood based on their expression of this antigen, utilizing either biotin-avidin affinity, panning or immunomagnetic beads. Roughly 50% of CD34+ cells, with 20-90% purity, are recovered from clinical samples using these methods. Several clinical trials have demonstrated hematopoietic recovery using CD34+ selected cells to support high dose therapy. CD34+ cells may be useful in several areas of clinical stem cell transplantation, including purging of tumor cells, T cell depletion, stem cell expansion and gene therapy. This paper reviews the current methods for purification of CD34+ cells from clinical samples and discusses potential uses of these cells in transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0027992737&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027992737&partnerID=8YFLogxK

M3 - Article

C2 - 7533577

AN - SCOPUS:0027992737

VL - 12

SP - 577

EP - 585

JO - Stem Cells

JF - Stem Cells

SN - 1066-5099

IS - 6

ER -